Navigation Links
Avanafil Data Presented at the European Society of Sexual Medicine Meeting
Date:12/5/2011

nse to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the teratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA's response to the NDA filed for avanafil; our ability to successfully commercialize or establish a marketing partnership for avanafil or our partner's ability to obtain regulatory approval to manufacture and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing efforts and our reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of initiation and completion of clinical trials and submissions to the FDA or foreign authorities; the volatility and liquidity of the
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting
2. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
3. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
4. Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
5. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
8. New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting
9. New Data on Vimpat® (lacosamide) C-V to Be Presented at the 65th Annual Meeting of the American Epilepsy Society
10. Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
11. XEOMIN® (incobotulinumtoxinA) Data to be Presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
(Date:7/30/2015)... July 30, 2015   Gaumard® Scientific Company ... UNI®, the world,s first operating system to support ... available exclusively to Gaumard users. UNI® version 2.27.21.0 ... Newborn Tory™ S2200, as well as improvements to ... clinical measures such as EtCO 2 .  ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3
... WASHINGTON, Sept. 29, 2011 As small businesses struggle ... indicates concern that forthcoming Essential Health Benefits regulations ... drug companies to raise prescription drug costs, the ... benefit managers (PBMs) administer drug benefits for thousands of ...
... 29, 2011 A drug recently approved by the U.S. ... targets a malfunctioning gene discovered more than a decade earlier ... scientific findings from St. Jude can be translated into therapies ... adults. The drug is Xalkori (crizotinib). The FDA ...
Cached Medicine Technology:Some Essential Benefits Rules Could Worry Small Businesses 2St. Jude Children's Research Hospital Discovery Aided Quest for Adult Cancer Drug 2St. Jude Children's Research Hospital Discovery Aided Quest for Adult Cancer Drug 3
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s ... It was also the first provider of Exilis non-surgical fat reduction in New York. ... it has attracted a large International clientele. Many patients travel to New York ...
(Date:7/31/2015)... ... 31, 2015 , ... Last week, the Mesothelioma Applied Research ... be accessed by visiting http://www.curemeso.org/store . , “Our new store features a ... whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” said ...
(Date:7/31/2015)... ... 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of ... Aesthetics released this new applicator in the United States as an upgrade to the ... The original applicator required a 2 hour treatment time. The new CoolSmooth ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... workshop at its new True North Conference Center. The medical community, social workers, ... Jacksonville community may be more aligned in the effort to better understand and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their flagship Organic ... the 2015 Vans US Open of Surfing, July 25 through August 2 in Huntington ... sugar” on the market, is a natural choice given the Open’s commitment to sustainable ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
... known that pregnant women who develop pre-eclampsia, which are a ... the risk of having a stroke during pregnancy. // ... Centres for Disease Control and Prevention now report that pre-eclampsia ... ,Dr David W. Brown and colleagues in Atlanta used ...
... rejected the UN findings that claim an extra 4,000 cancer ... Chernobyl disaster,// which struck 20 years ago. Instead, the group ... 93,000. ,Most of these victims would ... in April 1986 was one of the worst nuclear accidents ...
... Generally Vitamin D is found in either sunrays or in ... for that. // The research says that brief UV exposure ... D. The Food and Drug Administration proposed study is being ... to the concern with the vitamin deficiency. It would be ...
... died and up to 25,000 affected in a malaria epidemic in ... fanned out to take preventive steps and cure those hit by ... ,The minister said 50 people had died of cerebral malaria since ... Golaghat being the worst hit. ,"We have been able ...
... April issue of Archives of Dermatology, almost 50% of high ... their newspapers. // Tanning advertisements have been found in newspapers ... were about 40 tanning advertisements, 15 of whom did speak ... months. ,The article carries related information about the ...
... the lifestyle and socioeconomic status of 422 students with reference ... who lack sleep tend to be overweight //. ... Laval's faculty of medicine and was based on a telephonic ... children’s body mass index revealed that 24% of the girls ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: